Can a simple Self-Test cut preterm births in High-Risk pregnancies?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Pregnant woman over 18 years of age; * Single intra uterine pregnancy after 8 weeks and before 18 weeks of gestation (i.e. ≥ 8 weeks and ≤ 18 weeks). Woman can present symptomatic vaginal discharge, or can be asymptomatic or symptomatic with regard to the diagnosis of bacterial vaginosis (BV) with usual technics; * With a history of : * preterm birth before 37 weeks of gestation (even if the preterm birth was following preterm rupture of membranes); * and / or late miscarriage or fetal loss (i.e. miscarriage or foetal loss between 14 and 22 weeks of gestation), even if one any of her last birth occurred at term. * Woman having a reliable connexion by phone * Woman who has understood the study process and objectives and agreed to sign an informed consent form; * affiliated to a social security regimen or equivalent. Any eligible woman who will agree to participate in the study after being invited must sign a consent form before being included in the study. Women meeting all of these eligibility criteria will be invited even if they have oral or vaginal progestative treatment, cerclage or pessary, partially septate or arcuate uterus. Exclusion Criteria: * \- Woman of legal age under legal protection; * Women deprived of their freedom for administrative or legal reasons; * Woman who has not signed a consent form * Nulliparous; * Ectopic pregnancy; * Non-evolutive pregnancy or IUFD * Multiple pregnancy * Serious fetal malformation identified at first trimester screening such as cardiopathy, exencephaly, anasarque, gastroschisis, omphalocele, diaphragmatic hernia, cerebral or spinal major anomaly. * Woman participating in any clinical trial or intent to participate in another clinical trial, which may have an impact on flora or on prematurity rate, with or without investigational product at any time during the conduct of this study * Woman presenting contraindications to the study treatments: Hypersensitivity to the active substance or to any of the excipients * Woman presenting uterine malformation ( unicornuate, bicornuate, full septate) * Woman with preterm birth history because of twin pregnancy * Woman having received anti-infective treatment in the week preceding inclusion